Dr. Sher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
501 Deep Valley Dr
Suite 210
Rolling Hills Estates, CA 90274Phone+1 310-544-6858Fax+1 310-544-6855
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Allergy and Immunology, 1986 - 1989
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Pediatrics, 1983 - 1986
- University of Utah School of MedicineClass of 1983
Certifications & Licensure
- CA State Medical License 1984 - 2025
- American Board of Allergy and Immunology Allergy & Immunology
- American Board of Pediatrics Pediatrics
Awards, Honors, & Recognition
- Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
Clinical Trials
- Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy Start of enrollment: 2004 Oct 01
- Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome Start of enrollment: 2004 Oct 01
- Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine Start of enrollment: 2007 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 1036 citationsDupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled AsthmaMario Castro, Jonathan Corren, Ian D. Pavord, Jorge Maspero, Sally E. Wenzel
The New England Journal of Medicine. 2018-05-21 - 242 citationsEfficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.Eric L. Simpson, Amy S. Paller, Elaine C. Siegfried, Mark Boguniewicz, Lawrence Sher
JAMA Dermatology. 2020-01-01 - 15 citationsDupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial.Lawrence D Sher, Michael E Wechsler, Klaus F Rabe, Jorge F Maspero, Nadia Daizadeh
Chest. 2022-07-01
Press Mentions
- OCS-Sparing Effect of Dupilumab for Severe Asthma MaintainedJuly 23rd, 2022
- Pandemic-Weary LA County Crestfallen over News of Masks’ Return, Mere Weeks After Restrictions EasedJuly 15th, 2021
- Are We Declaring Pandemic over Too Fast? California’s June 15 Deadline for Reopening Splits ExpertsApril 8th, 2021
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: